R&D channel feed – Endpoints News

R&D channel feed

Novartis swings the ax again, this time aiming at 250 job cuts in the US

9 years ago

The FDA refuses to lift a clinical hold on Cel-Sci’s PhIII drug

9 years ago

Hard charging Neurocrine hit with a sudden setback as Tourette study flops

9 years ago

Bioverativ beefs up its pipeline of rare blood disease drugs with $825M True North buyout

9 years ago

Trump administration doubles down on slashing the budget at NIH, FDA — with a user fee hike for biopharma

9 years ago

On a deal spree, Takeda partners up with Nektar on a slate of cancer R&D combo studies

9 years ago

Shire writes off a shot at long-acting hemophilia drug after small study flops

9 years ago

Celgene scores another win for megablockbuster contender ozanimod, but it's haunted by key disability miss

9 years ago

La Jolla shares whacked as analysts spotlight disappointing PhIII fine print

9 years ago

Amgen’s star PhIII osteoporosis drug romo slammed by surprising cardio risk, a big plus for rival Radius drug

9 years ago

AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix

9 years ago

Top analyst says the tempest over drug prices will likely just die out without any major changes

9 years ago

The EMA rejects XBiotech’s cancer drug after an embarrassing PhIII — but they’re not giving up

9 years ago

Novartis is sending 500 jobs to the scrap heap while adding 350 ‘high-tech’ positions for growth

9 years ago

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO

9 years ago

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

9 years ago

#ASCO17: Epizyme will hunt a quick OK for tazemetostat, despite disappointing analysts with new data

9 years ago

#ASCO17: Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo

9 years ago

Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle

9 years ago

Novartis steps in to help seed a Michigan spinout’s move into the clinic with new eye drug

9 years ago

FDA forces Concert Pharma to hit the brakes on a mid-stage study so it can review tox studies

9 years ago

J&J pitches its top 11 drugs in the pipeline — with a peak sales promise of $1B-plus

9 years ago

Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study

9 years ago

Ionis says it gathered promising PhIII data for a top rare disease drug, but serious safety questions remain

9 years ago

First page Previous page 299 300 301302303 304 305 Next page Last page